A pathogenetic link between non-alcoholic fatty liver disease and celiac disease

Non-alcoholic fatty liver disease (NAFLD) has recently been recognized as the leading cause of the abnormalities in the liver function tests in the Western countries. Celiac disease (CD) is a permanent immunological intolerance to gluten proteins in genetically predisposed individuals. CD has been r...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine 2013-02, Vol.43 (1), p.65-67
Main Authors: Abenavoli, Ludovico, Milic, Natasa, De Lorenzo, Antonino, Luzza, Francesco
Format: Article
Language:English
Subjects:
Celiac Disease - diet therapy
Celiac Disease - metabolism
Celiac Disease - microbiology
Celiac Disease - physiopathology
Diabetes
Diet, Gluten-Free - adverse effects
Endocrinology
Fatty Liver - chemically induced
Fatty Liver - etiology
Fatty Liver - physiopathology
Gram-Negative Bacteria - growth & development
Gram-Negative Bacteria - metabolism
Gram-Positive Bacteria - growth & development
Gram-Positive Bacteria - metabolism
Humanities and Social Sciences
Humans
Internal Medicine
Intestines - metabolism
Intestines - microbiology
Lipopolysaccharides - metabolism
Lipopolysaccharides - pharmacokinetics
Lipopolysaccharides - toxicity
Liver - drug effects
Liver - physiopathology
Medicine
Medicine & Public Health
multidisciplinary
Non-alcoholic Fatty Liver Disease
Permeability
Science
Viewpoint
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-alcoholic fatty liver disease (NAFLD) has recently been recognized as the leading cause of the abnormalities in the liver function tests in the Western countries. Celiac disease (CD) is a permanent immunological intolerance to gluten proteins in genetically predisposed individuals. CD has been reported in 4–13 % of the cases with steatohepatitis, although the pathogenesis of the liver steatosis in CD patients is unclear. Based on the literature data, it can be concluded that the inclusion of serological markers of CD should be a part of the general workup in the patients with steatosis when other causes of the liver disease are excluded and in the patients with NAFLD when metabolic risk factors are not evident.
ISSN:1355-008X
1559-0100
DOI:10.1007/s12020-012-9731-y